Phlebotonics for haemorrhoids.
Identifieur interne : 004034 ( Main/Merge ); précédent : 004033; suivant : 004035Phlebotonics for haemorrhoids.
Auteurs : Nirmal Perera [Royaume-Uni] ; Danae Liolitsa ; Satheesh Iype ; Anna Croxford ; Muhammed Yassin ; Peter Lang ; Obioha Ukaegbu ; Christopher Van IssumSource :
- The Cochrane database of systematic reviews [ 1469-493X ] ; 2012.
Descripteurs français
- KwdFr :
- Diosmine (usage thérapeutique), Dobésilate de calcium (usage thérapeutique), Essais contrôlés randomisés comme sujet, Flavonoïdes (usage thérapeutique), Humains, Hémorroïdes (), Hémostatiques (usage thérapeutique), Ligature (), O-(bêta-Hydroxyéthyl)rutosides (analogues et dérivés), O-(bêta-Hydroxyéthyl)rutosides (usage thérapeutique), Soins postopératoires, Vasoconstricteurs (usage thérapeutique).
- MESH :
- analogues et dérivés : O-(bêta-Hydroxyéthyl)rutosides.
- usage thérapeutique : Diosmine, Dobésilate de calcium, Flavonoïdes, Hémostatiques, O-(bêta-Hydroxyéthyl)rutosides, Vasoconstricteurs.
- Essais contrôlés randomisés comme sujet, Humains, Hémorroïdes, Ligature, Soins postopératoires.
English descriptors
- KwdEn :
- Calcium Dobesilate (therapeutic use), Diosmin (therapeutic use), Flavonoids (therapeutic use), Hemorrhoids (therapy), Hemostatics (therapeutic use), Humans, Hydroxyethylrutoside (analogs & derivatives), Hydroxyethylrutoside (therapeutic use), Ligation (methods), Postoperative Care, Randomized Controlled Trials as Topic, Vasoconstrictor Agents (therapeutic use).
- MESH :
- chemical , analogs & derivatives : Hydroxyethylrutoside.
- chemical , therapeutic use : Calcium Dobesilate, Diosmin, Flavonoids, Hemostatics, Hydroxyethylrutoside, Vasoconstrictor Agents.
- methods : Ligation.
- therapy : Hemorrhoids.
- Humans, Postoperative Care, Randomized Controlled Trials as Topic.
Abstract
Haemorrhoids are variceal dilatations of the anal and perianal venous plexus and often develop secondary to the persistently elevated venous pressure within the haemorrhoidal plexus (Kumar 2005). Phlebotonics are a heterogenous class of drugs consisting of plant extracts (i.e. flavonoids) and synthetic compounds (i.e. calcium dobesilate). Although their precise mechanism of action has not been fully established, they are known to improve venous tone, stabilize capillary permeability and increase lymphatic drainage. They have been used to treat a variety of conditions including chronic venous insufficiency, lymphoedema and haemorrhoids.Numerous trials assessing the effect of phlebotonics in treating the symptoms and signs of haemorrhoidal disease suggest that there is a potential benefit.
DOI: 10.1002/14651858.CD004322.pub3
PubMed: 22895941
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001F98
- to stream PubMed, to step Curation: 001F98
- to stream PubMed, to step Checkpoint: 001F98
- to stream Ncbi, to step Merge: 005043
- to stream Ncbi, to step Curation: 005043
- to stream Ncbi, to step Checkpoint: 005043
Links to Exploration step
pubmed:22895941Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Phlebotonics for haemorrhoids.</title>
<author><name sortKey="Perera, Nirmal" sort="Perera, Nirmal" uniqKey="Perera N" first="Nirmal" last="Perera">Nirmal Perera</name>
<affiliation wicri:level="1"><nlm:affiliation>General Medicine, Addenbrookes Hospital, Cambridge, UK. perera.nirmal@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>General Medicine, Addenbrookes Hospital, Cambridge</wicri:regionArea>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liolitsa, Danae" sort="Liolitsa, Danae" uniqKey="Liolitsa D" first="Danae" last="Liolitsa">Danae Liolitsa</name>
</author>
<author><name sortKey="Iype, Satheesh" sort="Iype, Satheesh" uniqKey="Iype S" first="Satheesh" last="Iype">Satheesh Iype</name>
</author>
<author><name sortKey="Croxford, Anna" sort="Croxford, Anna" uniqKey="Croxford A" first="Anna" last="Croxford">Anna Croxford</name>
</author>
<author><name sortKey="Yassin, Muhammed" sort="Yassin, Muhammed" uniqKey="Yassin M" first="Muhammed" last="Yassin">Muhammed Yassin</name>
</author>
<author><name sortKey="Lang, Peter" sort="Lang, Peter" uniqKey="Lang P" first="Peter" last="Lang">Peter Lang</name>
</author>
<author><name sortKey="Ukaegbu, Obioha" sort="Ukaegbu, Obioha" uniqKey="Ukaegbu O" first="Obioha" last="Ukaegbu">Obioha Ukaegbu</name>
</author>
<author><name sortKey="Van Issum, Christopher" sort="Van Issum, Christopher" uniqKey="Van Issum C" first="Christopher" last="Van Issum">Christopher Van Issum</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22895941</idno>
<idno type="pmid">22895941</idno>
<idno type="doi">10.1002/14651858.CD004322.pub3</idno>
<idno type="wicri:Area/PubMed/Corpus">001F98</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F98</idno>
<idno type="wicri:Area/PubMed/Curation">001F98</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F98</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001F98</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001F98</idno>
<idno type="wicri:Area/Ncbi/Merge">005043</idno>
<idno type="wicri:Area/Ncbi/Curation">005043</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">005043</idno>
<idno type="wicri:Area/Main/Merge">004034</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Phlebotonics for haemorrhoids.</title>
<author><name sortKey="Perera, Nirmal" sort="Perera, Nirmal" uniqKey="Perera N" first="Nirmal" last="Perera">Nirmal Perera</name>
<affiliation wicri:level="1"><nlm:affiliation>General Medicine, Addenbrookes Hospital, Cambridge, UK. perera.nirmal@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>General Medicine, Addenbrookes Hospital, Cambridge</wicri:regionArea>
<wicri:noRegion>Cambridge</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liolitsa, Danae" sort="Liolitsa, Danae" uniqKey="Liolitsa D" first="Danae" last="Liolitsa">Danae Liolitsa</name>
</author>
<author><name sortKey="Iype, Satheesh" sort="Iype, Satheesh" uniqKey="Iype S" first="Satheesh" last="Iype">Satheesh Iype</name>
</author>
<author><name sortKey="Croxford, Anna" sort="Croxford, Anna" uniqKey="Croxford A" first="Anna" last="Croxford">Anna Croxford</name>
</author>
<author><name sortKey="Yassin, Muhammed" sort="Yassin, Muhammed" uniqKey="Yassin M" first="Muhammed" last="Yassin">Muhammed Yassin</name>
</author>
<author><name sortKey="Lang, Peter" sort="Lang, Peter" uniqKey="Lang P" first="Peter" last="Lang">Peter Lang</name>
</author>
<author><name sortKey="Ukaegbu, Obioha" sort="Ukaegbu, Obioha" uniqKey="Ukaegbu O" first="Obioha" last="Ukaegbu">Obioha Ukaegbu</name>
</author>
<author><name sortKey="Van Issum, Christopher" sort="Van Issum, Christopher" uniqKey="Van Issum C" first="Christopher" last="Van Issum">Christopher Van Issum</name>
</author>
</analytic>
<series><title level="j">The Cochrane database of systematic reviews</title>
<idno type="eISSN">1469-493X</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Calcium Dobesilate (therapeutic use)</term>
<term>Diosmin (therapeutic use)</term>
<term>Flavonoids (therapeutic use)</term>
<term>Hemorrhoids (therapy)</term>
<term>Hemostatics (therapeutic use)</term>
<term>Humans</term>
<term>Hydroxyethylrutoside (analogs & derivatives)</term>
<term>Hydroxyethylrutoside (therapeutic use)</term>
<term>Ligation (methods)</term>
<term>Postoperative Care</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Vasoconstrictor Agents (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Diosmine (usage thérapeutique)</term>
<term>Dobésilate de calcium (usage thérapeutique)</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Flavonoïdes (usage thérapeutique)</term>
<term>Humains</term>
<term>Hémorroïdes ()</term>
<term>Hémostatiques (usage thérapeutique)</term>
<term>Ligature ()</term>
<term>O-(bêta-Hydroxyéthyl)rutosides (analogues et dérivés)</term>
<term>O-(bêta-Hydroxyéthyl)rutosides (usage thérapeutique)</term>
<term>Soins postopératoires</term>
<term>Vasoconstricteurs (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Hydroxyethylrutoside</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Calcium Dobesilate</term>
<term>Diosmin</term>
<term>Flavonoids</term>
<term>Hemostatics</term>
<term>Hydroxyethylrutoside</term>
<term>Vasoconstrictor Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>O-(bêta-Hydroxyéthyl)rutosides</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Ligation</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hemorrhoids</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diosmine</term>
<term>Dobésilate de calcium</term>
<term>Flavonoïdes</term>
<term>Hémostatiques</term>
<term>O-(bêta-Hydroxyéthyl)rutosides</term>
<term>Vasoconstricteurs</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Postoperative Care</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
<term>Hémorroïdes</term>
<term>Ligature</term>
<term>Soins postopératoires</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Haemorrhoids are variceal dilatations of the anal and perianal venous plexus and often develop secondary to the persistently elevated venous pressure within the haemorrhoidal plexus (Kumar 2005). Phlebotonics are a heterogenous class of drugs consisting of plant extracts (i.e. flavonoids) and synthetic compounds (i.e. calcium dobesilate). Although their precise mechanism of action has not been fully established, they are known to improve venous tone, stabilize capillary permeability and increase lymphatic drainage. They have been used to treat a variety of conditions including chronic venous insufficiency, lymphoedema and haemorrhoids.Numerous trials assessing the effect of phlebotonics in treating the symptoms and signs of haemorrhoidal disease suggest that there is a potential benefit.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004034 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004034 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Merge |type= RBID |clé= pubmed:22895941 |texte= Phlebotonics for haemorrhoids. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:22895941" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |